Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES LAUNCH OF NEW U.K. CARDIOVASCULAR DRUG

 EATONTOWN, N.J. Dec. 2 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that its United Kingdom subsidiary, Monmouth Pharmaceuticals, Ltd., has received clearance from the United Kingdom Department of Health to launch ETHMOZINE(R), a new cardiovascular drug used to control cardiac arrhythmias or irregular heartbeats. ETHMOZINE was acquired recently by Roberts from Dupont- Merck Pharmaceuticals and is currently marketed by Roberts in the U.S. The launch of ETHMOZINE in the U.K. is the result of Roberts successful completion of the regulatory process involving the approval of the transfer of the product license to Monmouth Pharmaceuticals from Dupont- Merck by the local authorities. Monmouth fully expects to launch ETHMOZINE in the U.K. marketplace during the month of December.
 "The U.K. will be the second market for ETHMOZINE," said Dr. Robert Vukovich, Roberts Chairman and CEO. "Our marketing efforts in the U.S. for ETHMOZINE focus on increasing physician awareness of the unique pharmacologic profile of ETHMOZINE. The U.K. launch of ETHMOZINE will encompass the same marketing principles as those currently in place in the U.S.," he continued.
 Roberts Pharmaceutical Corporation is an international pharmaceutical company focusing on the acquisition and development of late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts currently markets its products in seven countries and has operating subsidiaries in the United States, Canada and the United Kingdom. Roberts has six prescription pharmaceutical products in late-stage clinical development and currently markets products primarily in six major therapeutic areas: Cardiovascular, Respiratory, Gynecology/Endocrinology, Urology, Oncology and Gastroenterology.
 -0- 12/2/93
 /CONTACT: Anthony Maris of Roberts Pharmaceutical Corporation, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PDT

JG -- NY036 -- 9776 12/02/93 11:48 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1993
Words:294
Previous Article:MEDAPHIS ANNOUNCES SEC EFFECTIVENESS OF COMMON STOCK OFFERING
Next Article:COOPER JOINT VENTURE RECEIVES GAS TURBINE ORDERS WORTH MORE THAN $60 MILLION FOR MOROCCO, CANADA AND THE NORTH SEA
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters